Rituximab + Lenalidomide + Valemetostat
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma
Conditions
Lymphoma
Trial Timeline
May 19, 2023 → Sep 30, 2027
NCT ID
NCT05683171About Rituximab + Lenalidomide + Valemetostat
Rituximab + Lenalidomide + Valemetostat is a phase 1/2 stage product being developed by Daiichi Sankyo for Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05683171. Target conditions include Lymphoma.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05683171 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFM13 | Affimed | Phase 2 | 44 |
| Pirtobrutinib + Brexucabtagene Autoleucel | Eli Lilly | Phase 2 | 52 |
| Enzastaurin | Eli Lilly | Phase 2 | 52 |
| Avastin + Gemcitabine + Oxaliplatin + Pegaspargase + Dexamethasone | Eli Lilly | Phase 2 | 52 |
| Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX) | Eli Lilly | Phase 2 | 52 |
| VIP152 + BTKi | Vincerx Pharma | Phase 1 | 25 |
| Tomivosertib (eFT-508) | eFFECTOR Therapeutics | Phase 1/2 | 33 |
| Nanatinostat in combination with valganciclovir | Viracta Therapeutics | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| Copanlisib + Rituximab | Celltrion | Phase 2 | 52 |
| Rituximab + Pembrolizumab | Celltrion | Phase 2 | 52 |
| Rituximab + Methotrexate + Cytarabine Injection | Celltrion | Phase 2 | 52 |
| rituximab | Celltrion | Phase 1 | 33 |
| CT-P10 + Rituxan | Celltrion | Phase 3 | 77 |
| Rituxan + CT-P10 + Cyclophosphamide + Vincristine + Prednisone | Celltrion | Phase 3 | 77 |
| Rituximab, lenalidomide | Celltrion | Phase 2 | 52 |
| Valemetostat tosylate | Daiichi Sankyo | Phase 2 | 52 |
| PLX3397 | Daiichi Sankyo | Phase 2 | 52 |
| Valemetostat Tosylate | Daiichi Sankyo | Phase 2 | 52 |
| HMPL-689 | HUTCHMED | Phase 1 | 28 |